Skip to menu Skip to content Skip to footer
Professor Simon Cool
Professor

Simon Cool

Email: 
Phone: 
+61 7 336 54175

Overview

Background

Professor Simon Cool is Professor of Bioengineering and Director of the UQ Advanced Cell Therapy Manufacturing Initiative in the School of Chemical Engineering at the University of Queensland.

Professor Cool began his scientific career at the University of Queensland more than 20 years ago. He received his BSc (hons) and PhD degrees from the University of Queensland, where he subsequently held a faculty position in the School of Biomedical Sciences. His areas of studies have included age-related changes in the structure of bone and teeth and the extracellular matrix compartment of skeletal tissue that guide stem cell behaviour and wound repair. Professor Cool was invited to join the Institute of Molecular and Cell Biology (IMCB), A*STAR, Singapore in 2003 as a Principal Investigator. He then joined A*STAR’s Institute of Medical Biology (IMB) in 2008, shortly after its inception, to further his research in regenerative medicine, serving as Senior Principal Investigator of the Glycotherapeutics Group. In October 2020, Professor Cool re-joined the Institute of Molecular and Cell Biology (IMCB) as a Research Director, Glycotherapeutics, where he focused on developing novel glycosaminoglycan biomolecules that enhance wound repair and control adult human mesenchymal stem cell activity.

Professor Cool has 117 patent applications across 26 families with 51 granted in the fields of glycosaminoglycan biochemistry, regenerative medicine and stem cell science. He has more than 150 publications and continues to foster strong strategic collaborations both nationally and internationally with academic and industry groups. He has a strong biomanufacturing and translational focus with experience in taking glycosaminoglycan-based devices through discovery RnD on to pre-clinical and clinical testing. Professor Cool also has an entrepreneurial and licensing background having successfully spun-off some of his technology to a US-based regenerative medicine start-up company, SMC Biotechnology Ltd. Professor Cool holds a Visiting Professor appointment at the Institute of Molecular and Cell Biology (IMCB), A*STAR, Singapore and an Adjunct Professor (Research) appointment in the Orthopaedic Department at the National University of Singapore (NUS). Prior to his move back to UQ, he previously held the position of Treasurer, Tissue Engineering and Regenerative Medicine International Society, Asia Pacific Chapter (TERMIS-AP) and Treasurer, Stem Cell Society Singapore (SCSS). He also held senior leadership positions in several Singapore-based R&D programmes, notably as Director, Allogeneic Stem Cell Manufacturing (ASTEM) and Theme Leader in Advanced Manufacturing for Biological Materials (AMBM). Prof Cool currently serves on the Editorial Board of the journals Biomaterials, Tissue Engineering and Regenerative Medicine, and is Asia-Pacific Regional Editor for Stem Cells and Development.

Availability

Professor Simon Cool is:
Available for supervision

Qualifications

  • Bachelor of Science (Honours), unknown
  • PhD, unknown

Research interests

  • Manufacturing highly-potent stem cells

    Developing novel media, assays, and processes to enable the scale-up manufacturing of cell therapy products.

  • Rejuvenation of ageing stem cells

    Developing innovative methods to rejuvenate ageing stem cells to generate best-in-class cell banks for therapeutic use.

  • Synthesis of glycosaminoglycans as medical devices

    Developing scalable methods to manufacture fully synthetic glycosaminoglycans for use as media additives, biocoatings and medical devices for treating disease, injury or trauma.

  • Modification of stem cells to improve their therapeutic utility

    Altering stem cell surfaces to encourage protein binding and drive stem cell fate decisions for improved therapeutic efficacy.

  • Enhanced angiogenesis through glycosaminoglycan administration and medical device formulation

    Developing pro-angiogenic microenvironments using novel glycosaminoglycan formulations.

Research impacts

I have over 25 years of leadership in identifying novel heparan sulphate (HS) glycosaminoglycan (GAG) sugars within stem cell niches and repairing tissues. These sugars sequester, protect, hold, and present key growth factors to stem cells. I have successfully used this complexation paradigm to unlock pathways critical to stem cell biology, mainly signalling cascades essential for maintaining naïve phenotypes. I have also shown that this strategy effectively develops bioadditives for manufacturing cell therapy devices for treating vascular ischemia/stroke, cartilage regeneration, and bone repair. A significant part of this pioneering effort has been manufacturing HS variants that mimic sugars in native tissues. Anchoring this strategy is my novel discovery platform that identifies specific domains in HS chains that form complexes with growth factors and growth factor receptors to generate powerful signalling complexes that mediate cell-fate decisions and potentiate tissue regeneration. Using this blueprint, I have developed a library of bio-inspired HS variants and subjected them to structure/function analyses. I strongly advocate for the safety/tolerability testing of HS materials and continue to lead industry-based projects in this area. I have considerable experience leading outcome-focused multidisciplinary research teams across all scientific discovery and translation aspects, with a proven track record in developing transformative technology and biotechnology entrepreneurship. I lead a long-standing effort to bank mesenchymal stem cells cultured in HS-supplemented media to treat age-related diseases (pre-clinical stage only) and have been working to transition this project to a commercial facility to develop suitable manufacturing and banking protocols for future clinical testing. Through these various opportunities, I have mentored numerous PhD students in Australia, Singapore, and the UK, which has helped accelerate research opportunities and led to significant gains in generating novel findings.

Works

Search Professor Simon Cool’s works on UQ eSpace

167 works between 1996 and 2025

101 - 120 of 167 works

2009

Journal Article

Wnt signaling controls the fate of mesenchymal stem cells

Ling, Ling, Nurcombe, Victor and Cool, Simon M. (2009). Wnt signaling controls the fate of mesenchymal stem cells. Gene, 433 (1-2), 1-7. doi: 10.1016/j.gene.2008.12.008

Wnt signaling controls the fate of mesenchymal stem cells

2009

Journal Article

Glycosaminoglycan composition changes with MG-63 osteosarcoma osteogenesis in vitro and induces human mesenchymal stem cell aggregation

Kumarasuriyar, A., Murali, S., Nurcombe, V. and Cool, S. M. (2009). Glycosaminoglycan composition changes with MG-63 osteosarcoma osteogenesis in vitro and induces human mesenchymal stem cell aggregation. Journal of Cellular Physiology, 218 (3), 501-511. doi: 10.1002/jcp.21620

Glycosaminoglycan composition changes with MG-63 osteosarcoma osteogenesis in vitro and induces human mesenchymal stem cell aggregation

2009

Journal Article

Osteoblasts up-regulate the expression of extracellular proteases following attachment to Poly(β-hydroxybutyrate-co-β-hydroxyvalerate)

Kumarasuriyar, Arjuna, Grondahl, Lisbeth, Nurcombe, Victor and Cool, Simon M. (2009). Osteoblasts up-regulate the expression of extracellular proteases following attachment to Poly(β-hydroxybutyrate-co-β-hydroxyvalerate). Gene, 428 (1-2), 53-58. doi: 10.1016/j.gene.2008.09.020

Osteoblasts up-regulate the expression of extracellular proteases following attachment to Poly(β-hydroxybutyrate-co-β-hydroxyvalerate)

2008

Conference Publication

Heparan sulfate promotes human mesenchymal stem cell growth and viability in vitro and stimulates bone repair in vivo

Sawyer, Amber A., Lim, Xinhong, Hosaka, Yoshi, Rider, David A., Poh, Wei Theng, Hui, James, Doshi, Hitendra, Nurcombe, Vic and Cool, Simon (2008). Heparan sulfate promotes human mesenchymal stem cell growth and viability in vitro and stimulates bone repair in vivo. World Biomaterials Congress, _, _.

Heparan sulfate promotes human mesenchymal stem cell growth and viability in vitro and stimulates bone repair in vivo

2008

Journal Article

Heparan sulfate mediates the proliferation and differentiation of rat mesenchymal stem cells

Dombrowski, Christian, Song, Shu Jun, Chuan, Peiying, Lim, Xinhong, Susanto, Evelyn, Sawyer, Amber A., Woodruff, Maria A., Hutmacher, Dietmar W., Nurcombe, Victor and Cool, Simon M. (2008). Heparan sulfate mediates the proliferation and differentiation of rat mesenchymal stem cells. Stem Cells and Development, 18 (4), 661-670. doi: 10.1089/scd.2008.0157

Heparan sulfate mediates the proliferation and differentiation of rat mesenchymal stem cells

2008

Journal Article

Stem Cell Fate Decisions: The Role of Heparan Sulfate in the Control of Autocrine and Paracrine Signals

Grunert, M., Nurcombe, V. and Cool, S. M. (2008). Stem Cell Fate Decisions: The Role of Heparan Sulfate in the Control of Autocrine and Paracrine Signals. Current Stem Cell Research and Therapy, 3 (1), 1-8. doi: 10.2174/157488808783489417

Stem Cell Fate Decisions: The Role of Heparan Sulfate in the Control of Autocrine and Paracrine Signals

2008

Journal Article

Autocrine fibroblast growth factor 2 increases the multipotentiality of human adipose-derived mesenchymal stem cells

Rider, D. A., Dombrowski, C., Sawyer, A. A., Ng, G. H., Leong, D., Hutmacher, D. W., Nurcombe, V. and Cool, S. M. (2008). Autocrine fibroblast growth factor 2 increases the multipotentiality of human adipose-derived mesenchymal stem cells. Stem Cells, 26 (6), 1598-1608. doi: 10.1634/stemcells.2007-0480

Autocrine fibroblast growth factor 2 increases the multipotentiality of human adipose-derived mesenchymal stem cells

2008

Journal Article

Combining electrospun scaffolds with electrosprayed hydrogels leads to three-dimensional cellularization of hybrid constructs

Ekaputra, A. K., Prestwich, G. D., Cool, S. M. and Hutmacher, D. W. (2008). Combining electrospun scaffolds with electrosprayed hydrogels leads to three-dimensional cellularization of hybrid constructs. Biomacromolecules, 9 (8), 2097-2103. doi: 10.1021/bm800565u

Combining electrospun scaffolds with electrosprayed hydrogels leads to three-dimensional cellularization of hybrid constructs

2008

Journal Article

A simple and reliable electroporation method for human bone marrow mesenchymal stem cells

Helledie, T., Nurcombe, V. and Cool, S. M. (2008). A simple and reliable electroporation method for human bone marrow mesenchymal stem cells. Stem Cells Dev, 17 (4), 837-848. doi: 10.1089/scd.2007.0209

A simple and reliable electroporation method for human bone marrow mesenchymal stem cells

2008

Journal Article

Elevated expression of Runx2 as a key parameter in the etiology of osteosarcoma

Nathan, S. S., Pereira, B. P., Zhou, Y. F., Gupta, A., Dombrowski, C., Soong, R., Pho, R. W., Stein, G. S., Salto-Tellez, M., Cool, S. M. and van Wijnen, A. J. (2008). Elevated expression of Runx2 as a key parameter in the etiology of osteosarcoma. Mol Biol Rep, 36 (1), 153-158. doi: 10.1007/s11033-008-9378-1

Elevated expression of Runx2 as a key parameter in the etiology of osteosarcoma

2007

Journal Article

Sustained release and osteogenic potential of heparan sulfate-doped fibrin glue scaffolds within a rat cranial model

Woodruff, Maria Ann, Rath, Subha Narayan, Susanto, Evelyn, Haupt, Larisa M., Hutmacher, Dietmar W., Nurcombe, Victor and Cool, Simon M. (2007). Sustained release and osteogenic potential of heparan sulfate-doped fibrin glue scaffolds within a rat cranial model. Journal of Molecular Histology, 38 (5), 425-433. doi: 10.1007/s10735-007-9137-y

Sustained release and osteogenic potential of heparan sulfate-doped fibrin glue scaffolds within a rat cranial model

2007

Journal Article

The in vivo assessment of a novel scaffold containing heparan sulfate for tissue engineering with human mesenchymal stem cells

Luong-Van, E, Grondahl, L, Song, SJ, Nurcombe, V and Cool, S (2007). The in vivo assessment of a novel scaffold containing heparan sulfate for tissue engineering with human mesenchymal stem cells. Journal of Molecular Histology, 38 (5), 459-468. doi: 10.1007/s10735-007-9129-y

The in vivo assessment of a novel scaffold containing heparan sulfate for tissue engineering with human mesenchymal stem cells

2007

Journal Article

Concepts of scaffold-based tissue engineering - The rationale to use solid free-form fabrication techniques

Hutmacher, D. W. and Cool, S. (2007). Concepts of scaffold-based tissue engineering - The rationale to use solid free-form fabrication techniques. Journal of Cellular and Molecular Medicine, 11 (4), 654-669. doi: 10.1111/j.1582-4934.2007.00078.x

Concepts of scaffold-based tissue engineering - The rationale to use solid free-form fabrication techniques

2007

Journal Article

Investigations into poly(3-hydroxybutyrate-co-3-hydroxyvalerate) surface properties causing delayed osteoblast growth

Keen, I., Raggatt, L.J., Cool, S.M., Nurcombe, V., Fredericks, P., Trau, M. and Grondahl, L. (2007). Investigations into poly(3-hydroxybutyrate-co-3-hydroxyvalerate) surface properties causing delayed osteoblast growth. Journal of Biomaterials Science-polymer Edition, 18 (9), 1101-1123. doi: 10.1163/156856207781554046

Investigations into poly(3-hydroxybutyrate-co-3-hydroxyvalerate) surface properties causing delayed osteoblast growth

2007

Journal Article

Poly(3-hydroxybutyrate-co-3-hydroxyvalerate) composite biomaterials for bone tissue regeneration: In vitro performance assessed by osteoblast proliferation, osteoclast adhesion and resorption, and macrophage proinflammatory response

Cool, SM, Kenny, B, Wu, A, Nurcombe, V, Trau, M, Cassady, AI and Grondahl, L (2007). Poly(3-hydroxybutyrate-co-3-hydroxyvalerate) composite biomaterials for bone tissue regeneration: In vitro performance assessed by osteoblast proliferation, osteoclast adhesion and resorption, and macrophage proinflammatory response. Journal of Biomedical Materials Research Part A, 82A (3), 599-610. doi: 10.1002/jbm.a.31174

Poly(3-hydroxybutyrate-co-3-hydroxyvalerate) composite biomaterials for bone tissue regeneration: In vitro performance assessed by osteoblast proliferation, osteoclast adhesion and resorption, and macrophage proinflammatory response

2007

Journal Article

In vitro biocompatibility and bioactivity of microencapsulated heparan sulfate

Luong-Van, E, Grondahl, L, Nurcombe, V and Cool, S (2007). In vitro biocompatibility and bioactivity of microencapsulated heparan sulfate. Biomaterials, 28 (12), 2127-2136. doi: 10.1016/j.biomaterials.2007.01.002

In vitro biocompatibility and bioactivity of microencapsulated heparan sulfate

2007

Journal Article

Control of cell fate decisions.

Cool SM (2007). Control of cell fate decisions.. Journal of Molecular Histology, 38 (5), 377-379. doi: 10.1007/s10735-007-9146-x

Control of cell fate decisions.

2007

Journal Article

Regulated expression of syndecan-4 in rat calvaria osteoblasts induced by fibroblast growth factor-2

Song, SJ, Cool, SM and Nurcombe, V (2007). Regulated expression of syndecan-4 in rat calvaria osteoblasts induced by fibroblast growth factor-2. Journal of Cellular Biochemistry, 100 (2), 402-411. doi: 10.1002/jcb.21068

Regulated expression of syndecan-4 in rat calvaria osteoblasts induced by fibroblast growth factor-2

2007

Journal Article

Disruption of heparan and chondroitin sulfate signaling enhances mesenchymal stem cell-derived osteogenic differentiation via bone morphogenetic protein signaling pathways.

Manton, KJ, Leong, DF, Cool, SM and Nurcombe, V (2007). Disruption of heparan and chondroitin sulfate signaling enhances mesenchymal stem cell-derived osteogenic differentiation via bone morphogenetic protein signaling pathways.. Stem Cells: the international journal of cell differentiation and proliferation, 25 (11), 2845-2854. doi: 10.1634/stemcells.2007-0065

Disruption of heparan and chondroitin sulfate signaling enhances mesenchymal stem cell-derived osteogenic differentiation via bone morphogenetic protein signaling pathways.

2007

Journal Article

A novel use of TAT-EGFP to validate techniques to alter osteosarcoma cell surface glycosaminoglycan expression

Kumarasuriyar, A, Dombrowski, C, Rider, DA, Nurcombe, V and Cool, SM (2007). A novel use of TAT-EGFP to validate techniques to alter osteosarcoma cell surface glycosaminoglycan expression. Journal of Molecular Histology, 38 (5), 435-447. doi: 10.1007/s10735-007-9136-z

A novel use of TAT-EGFP to validate techniques to alter osteosarcoma cell surface glycosaminoglycan expression

Funding

Past funding

  • 2003
    DEVELOPMENT OF A NOVEL BIOMATERIAL FOR BONE TISSUE ENGINEERING
    ARC Discovery Projects
    Open grant
  • 2001
    Fibroblast growth factors and their effects on bone mesenchymal stem cells.
    UQ Early Career Researcher
    Open grant
  • 2000 - 2003
    Promotion of bone healing by exogenous applications of growth factors
    Wesley Merdical Research
    Open grant
  • 1999
    Fibroblast growth factor: unlocking the secrets of osteoblast growth, differentiation and apoptosis.
    UQ New Staff Research Start-Up Fund
    Open grant

Supervision

Availability

Professor Simon Cool is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Supervision history

Current supervision

Completed supervision

Media

Enquiries

For media enquiries about Professor Simon Cool's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au